These results demonstrated that the nomogram combining expression of KRT19, RAET1G, IL12B, CXCL13, and CCL22 had better predictive power for the PFI of BRCA patients, which might contribute to the efficacy assessment and managing patients. This evidence concerns the gene CXCL13 and invasive breast carcinoma.